Drug Trial Radar · NCT07932691
Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Aug 9, 2024
Primary completion
Nov 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Beijing VDJBio Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study adopted a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose design, using recombinant human IL-2 fusion protein (VDJ010) administered subcutaneously to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy Chinese subjects and patients with ulcerative colitis.
Conditions
- Ulcerative Colitis (UC)
Interventions
Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010)Drug
VDJ010 is a recombinant fusion protein consisting of human interleukin-2 (IL-2) genetically fused to human serum albumin (HSA), produced using Chinese hamster ovary (CHO) cells through DNA recombinant technology. The fusion protein selectively binds to the high-affinity IL-2 receptor (IL-2Rαβγ) constitutively expressed on regulatory T cells (Treg), thereby promoting Treg expansion and restoring immune tolerance in autoimmune diseases such as ulcerative colitis. The HSA moiety extends the plasma half-life of IL-2 to enable less frequent subcutaneous dosing.
PlaceboDrug
This is a matching placebo formulation containing no active pharmaceutical ingredient (API). The placebo is manufactured to be identical in appearance, color, shape, size, and packaging to the investigational product VDJ010 to maintain the integrity of the double-blind design. It is utilized solely as a control intervention for the purpose of this randomized, double-blind, placebo-controlled Phase I clinical trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: First dose up to last follow-up visit (Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration)
- Peak Serum Concentration (Cmax)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
- Time to Peak Concentration (Tmax)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
- Area Under the Serum Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC0-∞)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Terminal Elimination Rate Constant (λz)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Terminal Elimination Half-Life (t1/2z)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Clearance (CLz)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Trough Concentration at Steady State (Cmin,ss / Ctrough,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Area Under the Curve over One Dosing Interval at Steady State (AUC0-τ,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Average Concentration at Steady State (Cav,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Degree of Fluctuation (DF)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- SwingTime frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Apparent Volume of Distribution at Steady State (Vss/F)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Apparent Clearance at Steady State (CLss/F)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Percentage of AUC Extrapolated to Infinity (AUC_%Extrap)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Mean Residence Time to Infinity (MRT0-∞)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Accumulation Ratio Based on Cmax (Ra(Cmax))Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- Accumulation Ratio Based on AUC (Ra(AUC))Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
- ImmunogenicityTime frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, Fujian, China · Not yet recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.